Complement System in Pathogenesis of AMD: Dual Player in Degeneration and Protection of Retinal Tissue

Journal of Immunology Research

Volumn 2014, Issue , 2014, Pages

  Kawa, Milosz P ^a   Machalinska, Anna ^a   Roginska, Dorota ^a   Machalinski, Boguslaw ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTIVE IMMUNITY; AGE RELATED MACULAR DEGENERATION; CELL SURVIVAL; CHOROID CAPILLARY LAYER; COMPLEMENT ACTIVATION; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT SYSTEM; CYTOLYSIS; EYE PROTECTION; GENE MUTATION; HUMAN; HUMORAL IMMUNITY; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NEUROPROTECTION; NONHUMAN; PATHOGENESIS; PIGMENT EPITHELIUM; PROTECTION; RETINA; RETINA DEGENERATION; RETINA MACULOPATHY; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TISSUE DEGENERATION; TISSUE INJURY; TISSUE PROTECTION; BIOLOGICAL MODEL; GENETICS; IMMUNOLOGY; MACULAR DEGENERATION; METABOLISM; MUTATION;

COMPLEMENT;

COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; HUMANS; MACULAR DEGENERATION; MODELS, IMMUNOLOGICAL; MUTATION; RETINA;

EID: 84928985230     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2014/483960     Document Type: Review

References (112)

1. D. S. Friedman, B. J. O'Colmain, B.Muñoz et al., "Prevalence of age-relatedmacular degeneration in theUnited States, " Archives of Ophthalmology, vol. 122, no. 4, pp. 564-572, 2004.
2. P. T. V. M. de Jong, "Age-related macular degeneration, " The New England Journal ofMedicine, vol. 355, no. 14, pp. 1474-1485, 2006.
3. D. S. Friedman, M. X. Repka, J. Katz et al., "Prevalence of decreased visual acuity among preschool-aged children in an American urban population: the Baltimore Pediatric Eye Disease Study, methods, and results, " Ophthalmology, vol. 115, no. 10, pp. 1786-1795, 2008.
4. R. Klein, B. E. K. Klein, S. C. Jensen, and S. M.Meuer, "The fiveyear incidence and progression of age-related maculopathy: the beaver dam eye study, " Ophthalmology, vol. 104, no. 1, pp. 7-21, 1997.
5. I. Bhutto and G. Lutty, "Understanding age-related macular degeneration (AMD): relationships between the photoreceptor/retinal pigment epithelium/Bruch'smembrane/choriocapillaris complex, " Molecular Aspects of Medicine, vol. 33, no. 4, pp. 295-317, 2012.
6. A. Swaroop, E. Y. Chew, C. B. Rickman, and G. R. Abecasis, "Unraveling a multifactorial late-onset disease: From genetic susceptibility to disease mechanisms for age-related macular degeneration, " Annual Review of Genomics and Human Genetics, vol. 10, pp. 19-43, 2009.
7. J. R. Sparrow, K. Ueda, and J. Zhou, "Complement dysregulation in AMD: RPE-Bruch's membrane-choroid, " Molecular Aspects of Medicine, vol. 33, no. 4, pp. 436-445, 2012.
8. D. H. Anderson, R. F. Mullins, G. S. Hageman, and L. V. Johnson, "A role for local inflammation in the formation of drusen in the aging eye, " American Journal of Ophthalmology, vol. 134, no. 3, pp. 411-431, 2002.
9. M. B. Gorin, "Genetic insights into age-related macular degeneration: controversies addressing risk, causality, and therapeutics, " Molecular Aspects of Medicine, vol. 33, no. 4, pp. 467-486, 2012.
10. A. MacHalínska, V. Dziedziejko, K. Mozolewska-Piotrowska, D. Karczewicz, B.Wiszniewska, and B. MacHalínski, "Elevated plasma levels of c3a complement compound in the exudative form of age-related macular degeneration, " Ophthalmic Research, vol. 42, no. 1, pp. 54-59, 2009.
11. P. Gasque, "Complement: a unique innate immune sensor for danger signals, "Molecular Immunology, vol. 41, no. 11, pp. 1089-1098, 2004.
12. C. A. Janeway Jr., P. Travers, M. Walport, andM. J. Shlomchik, "The complement system and innate immunity, " in Immunobiology : The Immune System in Health and Disease, Garland Science, New York, NY, USA, 5th edition, 2001.
13. D. H. Anderson, M. J. Radeke, N. B. Gallo et al., "The pivotal role of the complement systemin aging and age-related macular degeneration: hypothesis re-visited, " Progress in Retinal and Eye Research, vol. 29, no. 2, pp. 95-112, 2010.
14. J.W. Crabb, M.Miyagi, X. Gu et al., "Drusen proteome analysis: an approach to the etiology of age-related macular degeneration, " Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 23, pp. 14682-14687, 2002.
15. R. F.Mullins, S. R. Russell, D. H. Anderson, and G. S.Hageman, "Drusen associated with aging and age-relatedmacular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease, " FASEB Journal, vol. 14, no. 7, pp.835-846, 2000.
16. L. V. Johnson, W. P. Leitner, M. K. Staples, and D. H. Anderson, "Complement activation and inflammatory processes in drusen formation and age related macular degeneration, " Experimental Eye Research, vol. 73, no. 6, pp. 887-896, 2001.
17. L. V. Johnson, S. Ozaki, M. K. Staples, P. A. Erickson, and D. H. Anderson, "A potential role for immune complex pathogenesis in drusen formation, " Experimental Eye Research, vol. 70, no. 4, pp. 441-449, 2000.
18. H. Chen, B. Liu, T. J. Lukas, and A. H. Neufeld, "The aged retinal pigment epithelium/choroid: a potential substratum for the pathogenesis of age-related macular degeneration, " PLoS ONE, vol. 3, no. 6, Article ID e2339, 2008.
19. J. C. Booij, S. van Soest, S. M. A. Swagemakers et al., "Functional annotation of the human retinal pigment epithelium transcriptome, " BMC Genomics, vol. 10, article 164, 2009.
20. M. Chen, E. Muckersie, M. Robertson, J. V. Forrester, and H. Xu, "Up-regulation of complement factor B in retinal pigment epithelial cells is accompanied by complement activation in the aged retina, " Experimental Eye Research, vol. 87, no. 6, pp. 543-550, 2008.
21. M. Chen, J. V. Forrester, and H. Xu, "Synthesis of complement factor H by retinal pigment epithelial cells is down-regulated by oxidized photoreceptor outer segments, " Experimental Eye Research, vol. 84, no. 4, pp. 635-645, 2007.
22. Y. H. Kim, S. He, S. Kase, M. Kitamura, S. J. Ryan, and D. R. Hinton, "Regulated secretion of complement factor H by RPE and its role in RPE migration, " Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 247, no. 5, pp. 651-659, 2009.
23. N. Kociok and A. M. Joussen, "Enhanced expression of the complement factor HmRNA in proliferating human RPE cells, " Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 248, no. 8, pp. 1145-1153, 2010.
24. P. Yang, J. Tyrrell, I. Han, and G. J. Jaffe, "Expression and modulation of RPE cell membrane complement regulatory proteins, " Investigative Ophthalmology and Visual Science, vol. 50, no. 7, pp. 3473-3481, 2009.
25. N. S. Bora, S. Kaliappan, P. Jha et al., "CD59, a complement regulatory protein, controls choroidal neovascularization in a mouse model of wet-type age-related macular degeneration, " The Journal of Immunology, vol. 178, no. 3, pp. 1783-1790, 2007.
26. L. Soane, H. Rus, F. Niculescu, and M. L. Shin, "Inhibition of oligodendrocyte apoptosis by sublytic C5b-9 is associated with enhanced synthesis of Bcl-2 and mediated by inhibition of caspase-3 activation, " Journal of Immunology, vol. 163, no. 11, pp. 6132-6138, 1999.
27. S. Hila, L. Soane, and C. L. Koski, "Sublytic C5b-9-stimulated Schwann cell survival through PI 3-kinase-mediated phosphorylation of BAD, " Glia, vol. 36, no. 1, pp. 58-67, 2001.
28. H. G. Rus, F. Niculescu, and M. L. Shin, "Sublytic complement attack induces cell cycle in oligodendrocytes: S phase induction is dependent on c-jun activation, " Journal of Immunology, vol. 156, no. 12, pp. 4892-4900, 1996.
29. A. O. Edwards and G. Malek, "Molecular genetics of AMD and current animal models, " Angiogenesis, vol. 10, no. 2, pp. 119-132, 2007.
30. J. M. Seddon, J. Cote, W. F. Page, S. H. Aggen, and M. C. Neale, "The US twin study of age-related macular degeneration: relative roles of genetic and environmental influences, " Archives of Ophthalmology, vol. 123, no. 3, pp. 321-327, 2005.
31. Y.Yu, T. R. Bhangale, J. Fagerness et al., "Commonvariants near FRK/COL10A1 and VEGFA are associated with advanced agerelated macular degeneration, " Human Molecular Genetics, vol. 20, no. 18, pp. 3699-3709, 2011.
32. L. G. Fritsche, W. Chen, M. Schu et al., "Seven new loci associated with age-related macular degeneration, " Nature Genetics, vol. 45, no. 4, pp. 433-439, 2013.
33. H. P. N. Scholl, M. Fleckenstein, L. G. Fritsche et al., "CFH, C3 and ARMS2 are significant risk loci for susceptibility but not for disease progression of geographic atrophy due to AMD, " PLoS ONE, vol. 4, no. 10, Article IDe7418, 2009.
34. B. Gold, J. E. Merriam, J. Zernant et al., "Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration, " Nature Genetics, vol. 38, no. 4, pp. 458-462, 2006.
35. 3 are associatedwith progression to advanced age related macular degeneration associated with visual loss, " Journal of Medical Genetics, vol. 46, no. 5, pp. 300-307, 2009.
36. G. J. McKay, G. Silvestri, C. C. Patterson, R. E. Hogg, U. Chakravarthy, and A. E. Hughes, "Further assessment of the complement component 2 and factor B region associated with agerelatedmacular degeneration, " Investigative Ophthalmology and Visual Science, vol. 50, no. 2, pp. 533-539, 2009.
37. K. L. Spencer, M. A.Hauser, L. M. Olson et al., "Protective effect of complement factor B and complement component 2 variants in age-relatedmacular degeneration, " HumanMolecular Genetics, vol. 16, no. 16, pp. 1986-1992, 2007.
38. T. Montes, A. Tortajada, B. P. Morgan, S. R. De Córdoba, and C. L. Harris, "Functional basis of protection against age-related macular degeneration conferred by a common polymorphism in complement factor B, " Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 11, pp. 4366-4371, 2009.
39. I. Kaur, S. Katta, R. K. Reddy et al., "The involvement of complement factor B and complement component C2 in an Indian cohort with age-related macular degeneration, " Investigative Ophthalmology and Visual Science, vol. 51, no. 1, pp. 59-63, 2010.
40. J. Maller, S. George, S. Purcell et al., "Common variation in three genes, including a noncoding variant in CFH, strongly influences risk of age-related macular degeneration, " Nature Genetics, vol. 38, no. 9, pp. 1055-1059, 2006.
41. A. J. Richardson, F. M. Amirul Islam, R. H. Guymer, and P. N. Baird, "Analysis of rare variants in the complement component 2 (C2) and factor B (BF) genes refine association for age-related macular degeneration (AMD), " Investigative Ophthalmology and Visual Science, vol. 50, no. 2, pp. 540-543, 2009.
42. J. Jakobsdottir, Y. P. Conley, D. E. Weeks, R. E. Ferrell, and M. B. Gorin, "C2 and CFB genes in Age-related maculopathy and joint action with CFH and LOC387715 genes, " PLoS ONE, vol. 3, no. 5, Article ID e2199, 2008.
43. I. Peter, G. S. Huggins, J. M. Ordovas, M. Haan, and J. M. Seddon, "Evaluation of new and established age-related macular degeneration susceptibility genes in the Women's Health Initiative Sight Exam (WHI-SE) study, " The American Journal of Ophthalmology, vol. 152, no. 6, pp. 1005-1013, 2011.
44. V. Dinu, P. L. Miller, and H. Zhao, "Evidence for association between multiple complement pathway genes and AMD, " Genetic Epidemiology, vol. 31, no. 3, pp. 224-237, 2007.
45. A. O. Edwards, R. Ritter III, K. J. Abel, A.Manning, C. Panhuysen, and L.A. Farrer, "Complement factor H polymorphism and age-related macular degeneration, " Science, vol. 308, no. 5720, pp. 421-424, 2005.
46. J. L.Haines, M.A.Hauser, S. Schmidt et al., "Complement factor H variant increases the risk of age-related macular degeneration, " Science, vol. 308, no. 5720, pp. 419-421, 2005.
47. R. J. Klein, C. Zeiss, E. Y. Chew et al., "Complement factor H polymorphism in age-related macular degeneration, " Science, vol. 308, no. 5720, pp. 385-389, 2005.
48. K. L. Spencer, M. A. Hauser, L. M. Olson et al., "Haplotypes spanning the complement factor H gene are protective against age-relatedmacular degeneration, " Investigative Ophthalmology and Visual Science, vol. 48, no. 9, pp. 4277-4283, 2007.
49. G. S. Hageman, D. H. Anderson, L. V. Johnson et al., "A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration, " Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 20, pp. 7227-7232, 2005.
50. H. Okamoto, S.Umeda, M. Obazawa et al., "Complement factor H polymorphisms in Japanese population with age-related macular degeneration, " Molecular Vision, vol. 12, pp. 156-158, 2006.
51. L. J. Kopplin, R. P. Igo, Y. Wang Jr. et al., "Genome-wide association identifies SKIV2L and MYRIP as protective factors for age-relatedmacular degeneration, " Genes and Immunity, vol. 11, no. 8, pp. 609-621, 2010.
52. W. Chen, D. Stambolian, A. O. Edwards et al., "Genetic variants near TIMP3 and high-density lipoprotein-associated loci influence susceptibility to age-related macular degeneration, " Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 16, pp. 7401-7406, 2010.
53. A. E. Hughes, N. Orr, H. Esfandiary, M. Diaz-Torres, T. Goodship, and U. Chakravarthy, "A common CFH haplotype, with deletion of CFHR1 and CFHR3, is associated with lower risk of age-related macular degeneration, " Nature Genetics, vol. 38, no. 10, pp. 1173-1177, 2006.
54. L. G. Fritsche, N. Lauer, A. Hartmann et al., "An imbalance of human complement regulatory proteins CFHR1, CFHR3 and factor H influences risk for age-related macular degeneration (AMD), " Human Molecular Genetics, vol. 19, no. 23, pp. 4694-4704, 2010.
55. S. Raychaudhuri, O. Iartchouk, K. Chin et al., "A rare penetrant mutation in CFH confers high risk of age-related macular degeneration, " Nature Genetics, vol. 43, no. 12, pp. 1232-1236, 2011.
56. U. Narendra, G. J. T. Pauer, and S. A. Hagstrom, "Genetic analysis of complement factor H related 5, CFHR5, in patients with age-related macular degeneration, " Molecular Vision, vol. 15, pp. 731-736, 2009.
57. M. Heurich, R. Martínez-Barricarte, N. J. Francis et al., "Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic complement activity and disease risk, " Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 21, pp. 8761-8766, 2011.
58. A. Tortajada, T. Montes, R. Martínez-Barricarte, B. P. Morgan, C. L. Harris, and S. R. de Córdoba, "The disease-protective complement factor H allotypic variant Ile62 shows increased binding affinity for C3b and enhanced cofactor activity, " Human Molecular Genetics, vol. 18, no. 18, pp. 3452-3461, 2009.
59. J. A. Fagerness, J. B. Maller, B. M. Neale, R. C. Reynolds, M. J. Daly, and J. M. Seddon, "Variation near complement factor I is associated with risk of advanced AMD, " European Journal of Human Genetics, vol. 17, no. 1, pp. 100-104, 2009.
60. E.An, S. Sen, S. K. Park, H.Gordish-Dressman, andY.Hathout, "Identification of novel substrates for the serine protease HTRA1 in the human RPE secretome, " Investigative Ophthalmology and Visual Science, vol. 51, no. 7, pp. 3379-3386, 2010.
61. G. S. Hageman, L. S. Hancox, A. J. Taiber et al., "Extended haplotypes in the complement factor H (CFH) and CFH-related (CFHR) family of genes protect against age-related macular degeneration: characterization, ethnic distribution and evolutionary implications, " Annals ofMedicine, vol. 38, no. 8, pp. 592-604, 2006.
62. S. Heinen, A. Hartmann, N. Lauer et al., "Factor H-related protein 1 (CFHR-1) inhibits complement C5 convertase activity and terminal complex formation, " Blood, vol. 114, no. 12, pp. 2439-2447, 2009.
63. S. R. de Cordoba, A. Tortajada, C. L. Harris, and B. P. Morgan, "Complement dysregulation and disease: from genes and proteins to diagnostics and drugs, " Immunobiology, vol. 217, no. 11, pp. 1034-1046, 2012.
64. A. Thakkinstian, G. J. McKay, M. McEvoy et al., "Systematic review and meta-analysis of the association between complement component 3 and age-related macular degeneration: a HuGE review and meta-analysis, " The American Journal of Epidemiology, vol. 173, no. 12, pp. 1365-1379, 2011.
65. R. Reynolds, M. E. Hartnett, J. P. Atkinson, P. C. Giclas, B. Rosner, and J. M. Seddon, "Plasma complement components and activation fragments: associations with age-relatedmacular degeneration genotypes and phenotypes, " InvestigativeOphthalmology and Visual Science, vol. 50, no. 12, pp. 5818-5827, 2009.
66. L. A.Hecker, A.O. Edwards, E. Ryu et al., "Genetic control of the alternative pathway of complement in humans and age-related macular degeneration, " Human Molecular Genetics, vol. 19, no. 1, pp. 209-215, 2009.
67. H. P.N. Scholl, P.C. Issa, M.Walier et al., "Systemic complement activation in age-relatedmacular degeneration, " PLoS ONE, vol. 3, no. 7, Article ID e2593, 2008.
68. C. A. Curcio, J. B. Presley, C. L. Millican, and N. E. Medeiros, "Basal deposits and drusen in eyes with age-related maculopathy: evidence for solid lipid particles, " Experimental Eye Research, vol. 80, no. 6, pp. 761-775, 2005.
69. C. Li, B. H. Chung, J. B. Presley et al., "Lipoprotein-like particles and cholesteryl esters in human Bruch's membrane: initial characterization, " Investigative Ophthalmology and Visual Science, vol. 46, no. 7, pp. 2576-2586, 2005.
70. L.Wang, M. E. Clark, D. K. Crossman et al., "Abundant lipid and protein components of drusen, " PLoS ONE, vol. 5, no. 4, Article ID e10329, 2010.
71. F. L. Ferris, M.D.Davis, T. E. Clemons et al., "Asimplified severity scale for age-related macular degeneration: AREDS report no. 18, " Archives ofOphthalmology, vol. 123, no. 11, pp. 1570-1574, 2005.
72. G. Malek, C. M. Li, C. Guidry, N. E. Medeiros, and C. A. Curcio, "Apolipoprotein B in cholesterol-containing drusen and basal deposits of human eyes with age-related maculopathy, " The American Journal of Pathology, vol. 162, no. 2, pp. 413-425, 2003.
73. L. V. Johnson, D. L. Forest, C. D. Banna et al., "Cell culture model that mimics drusen formation and triggers complement activation associated with age-related macular degeneration, " Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 45, pp. 18277-18282, 2011.
74. D.H.Anderson, K. C. Talaga, A. J.Rivest, E. Barron, G. S.Hageman, and L. V. Johnson, "Characterization of β amyloid assemblies in drusen: the deposits associated with aging and agerelated macular degeneration, " Experimental Eye Research, vol. 78, no. 2, pp. 243-256, 2004.
75. L. V. Johnson, W. P. Leitner, A. J. Rivest, M. K. Staples, M. J. Radeke, and D. H. Anderson, "The Alzheimer's Aβ-peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration, " Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 18, pp. 11830-11835, 2002.
76. M. A. Zarbin, "Current concepts in the pathogenesis of agerelated macular degeneration, " Archives of Ophthalmology, vol. 122, no. 4, pp. 598-614, 2004.
77. J. M.Thurman, B. Renner, K. Kunchithapauthamet al., "Oxidative stress renders retinal pigment epithelial cells susceptible to complement-mediated injury, " Journal of Biological Chemistry, vol. 284, no. 25, pp. 16939-16947, 2009.
78. S. L. Doyle, M. Campbell, E. Ozaki et al., "NLRP3 has a protective role in age-related macular degeneration through the induction of IL-18 by drusen components, " Nature Medicine, vol. 18, no. 5, pp. 791-798, 2012.
79. V. Hornung, F. Bauernfeind, A. Halle et al., "Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization, " Nature Immunology, vol. 9, no. 8, pp. 847-856, 2008.
80. P. S. Bora, J. Sohn, J. M. C. Cruz et al., "Role of complement and complement membrane attack complex in laser-induced choroidal neovascularization, " Journal of Immunology, vol. 174, no. 1, pp. 491-497, 2005.
81. N. S. Bora, S. Kaliappan, P. Jha et al., "Complement activation via alternative pathway is critical in the development of laserinduced choroidal neovascularization: role of factor B and factor H, " The Journal of Immunology, vol. 177, no. 3, pp. 1872-1878, 2006.
82. M. Nozaki, B. J. Raisler, E. Sakurai et al., "Drusen complement components C3a and C5a promote choroidal neovascularization, " Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 7, pp. 2328-2333, 2006.
83. V. V. Lyzogubov, R. G. Tytarenko, P. Jha, J. Liu, N. S. Bora, and P. S. Bora, "Role of ocular complement factor H in a murine model of choroidal neovascularization, " The American Journal of Pathology, vol. 177, no. 4, pp. 1870-1880, 2010.
84. L. R. Benzaquen, A. Nicholson-Weller, and J. A. Halperin, "Terminal complement proteins C5b-9 release basic fibroblast growth factor and platelet-derived growth factor fromendothelial cells, " Journal of Experimental Medicine, vol. 179, no. 3, pp. 985-992, 1994.
85. S. M. Cashman, A. Desai, K. Ramo, and R. Kumar-Singh, "Expression of complement component 3 (C3) from an adenovirus leads to pathology in the murine retina, " Investigative Ophthalmology and Visual Science, vol. 52, no. 6, pp. 3436-3445, 2011.
86. R.Medzhitov, "Origin and physiological roles of inflammation, " Nature, vol. 454, no. 7203, pp. 428-435, 2008.
87. J. Van Beek, K. Elward, and P. Gasque, "Activation of complement in the central nervous system: roles in neurodegeneration and neuroprotection, " Annals of the New York Academy of Sciences, vol. 992, pp. 56-71, 2003.
88. K. Pisalyaput and A. J. Tenner, "Complement component C1q inhibits β-amyloid-and serum amyloid P-induced neurotoxicity via caspase-and calpain-independent mechanisms, " Journal of Neurochemistry, vol. 104, no. 3, pp. 696-707, 2008.
89. M. E. Benoit and A. J. Tenner, "Complement protein C1q-mediated neuroprotection is correlated with regulation of neuronal gene and microRNA expression, " The Journal of Neuroscience, vol. 31, no. 9, pp. 3459-3469, 2011.
90. M.Maier, Y. Peng, L. Jiang, T. J. Seabrook, M. C. Carroll, and C. A. Lemere, "Complement C3 deficiency leads to accelerated amyloid β plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice, " Journal of Neuroscience, vol. 28, no. 25, pp. 6333-6341, 2008.
91. J. H. Kam, E. Lenassi, T. H. Malik, M. C. Pickering, and G. Jeffery, "Complement component C3 plays a critical role in protecting the aging retina in a murine model of age-related macular degeneration, " The American Journal of Pathology, vol. 183, no. 2, pp. 480-492, 2013.
92. J. Liu, F. Lin, M. G. Strainic et al., "IFN-γ and IL-17 production in experimental autoimmune encephalomyelitis depends on local APC-T cell complement production, " The Journal of Immunology, vol. 180, no. 9, pp. 5882-5889, 2008.
93. D.Ricklin, G.Hajishengallis, K. Yang, and J. D. Lambris, "Complement: a key system for immune surveillance and homeostasis, " Nature Immunology, vol. 11, no. 9, pp. 785-797, 2010.
94. T. Takabayashi, E. Vannier, J. F. Burke, R. G. Tompkins, J. A. Gelfand, and B. D. Clark, "Both C3a and C3a(desArg) regulate interleukin-6 synthesis in human peripheral blood mononuclear cells, " Journal of InfectiousDiseases, vol. 177, no.6, pp. 1622-1628, 1998.
95. T. Takabayashi, E. Vannier, B. D. Clark et al., "A new biologic role for C3a and C3a desArg: regulation of TNF-α and IL-1β synthesis, " The Journal of Immunology, vol. 156, no. 9, pp. 3455-3460, 1996.
96. J. van Beek, O. Nicole, C. Ali et al., "Complement anaphylatoxin c3a is selectively protective against nmda-induced neuronal cell death, " NeuroReport, vol. 12, no. 2, pp. 289-293, 2001.
97. A. Jauneau, A. Ischenko, A. Chatagner et al., "Interleukin-1β and anaphylatoxins exert a synergistic effect onNGF expression by astrocytes, " Journal of Neuroinflammation, vol. 3, article 8, 2006.
98. K. Heese, C. Hock, and U. Otten, "Inflammatory signals induce neurotrophin expression in human microglial cells, " Journal of Neurochemistry, vol. 70, no. 2, pp. 699-707, 1998.
99. H. Osaka, P. Mukherjee, P. S. Aisen, and G. M. Pasinetti, "Complement-derived anaphylatoxin C5a protects against glutamate-mediated neurotoxicity, " Journal of Cellular Biochemistry, vol. 73, no. 3, pp. 303-311, 1999.
100. S. P. Kastl, W. S. Speidl, C. Kaun et al., "The complement component C5a induces the expression of plasminogen activator inhibitor-1 in human macrophages via NF-κB activation, " Journal of Thrombosis and Haemostasis, vol. 4, no. 8, pp. 1790-1797, 2006.
101. P. A. Ward, "Functions of C5a receptors, " Journal of Molecular Medicine, vol. 87, no. 4, pp. 375-378, 2009.
102. Q. Peng, K. Li, N. Wang et al., "Dendritic cell function in allostimulation is modulated by C5aR signaling, " The Journal of Immunology, vol. 183, no. 10, pp. 6058-6068, 2009.
103. J. M. Thurman, A. M. Lenderink, P. A. Royer et al., "C3a is required for the production of CXC chemokines by tubular epithelial cells after renal ishemia/reperfusion, " The Journal of Immunology, vol. 178, no. 3, pp. 1819-1828, 2007.
104. C. B. Martin, S.A. Ingersoll, and B. K. Martin, "Transcriptional control of the C3a receptor gene in glial cells: dependence upon AP-1 but not Ets, "Molecular Immunology, vol. 44, no. 5, pp. 703-712, 2007.
105. M.G. Strainic, J. Liu, D.Huang et al., "Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells, " Immunity, vol. 28, no. 3, pp. 425-435, 2008.
106. M. Yu, W. Zou, N. S. Peachey, T. M. McIntyre, and J. Liu, "A novel role of complement in retinal degeneration, " Investigative Ophthalmology and Visual Science, vol. 53, no. 12, pp. 7684-7692, 2012.
107. P. Mukherjee and G. M. Pasinetti, "Complement anaphylatoxin C5a neuroprotects through mitogen-activated protein kinasedependent inhibition of caspase 3, " Journal of Neurochemistry, vol. 77, no. 1, pp. 43-49, 2001.
108. P. Mukherjee, S. Thomas, and G. M. Pasinetti, "Complement anaphylatoxin C5a neuroprotects through regulation of glutamate receptor subunit 2 in vitro and in vivo, " Journal of Neuroinflammation, vol. 5, article 5, 2008.
109. P. Mukherjee and G. M. Pasinetti, "The role of complement anaphylatoxin C5a in neurodegeneration: implications in Alzheimer's disease, " Journal of Neuroimmunology, vol. 105, no. 2, pp. 124-130, 2000.
110. N. Shinjyo, A. Stahlberg, M. Dragunow, M. Pekny, and M. Pekna, "Complement-derived anaphylatoxin C3a regulates in vitro differentiation and migration of neural progenitor cells, " Stem Cells, vol. 27, no. 11, pp. 2824-2832, 2009.
111. S. A. Ingersoll, C. B. Martin, S. R. Barnum, and B. K. Martin, "CNS-specific expression of C3a and C5a exacerbate demyelination severity in the cuprizonemodel, "Molecular Immunology, vol. 48, no. 1-3, pp. 219-230, 2010.
112. Y. Rahpeymai, M. A. Hietala, U. Wilhelmsson et al., "Complement: a novel factor in basal and ischemia-induced neurogenesis, " EMBO Journal, vol. 25, no. 6, pp. 1364-1374, 2006.